Population-based Cervical Cancer Screening Using High-risk HPV DNA Test and Liquid-based Cytology in Northern Thailand |
Siriaunkgul, Sumalee
(Department of Pathology, Faculty of Medicine, Chiang Mai University)
Settakorn, Jongkolnee (Department of Pathology, Faculty of Medicine, Chiang Mai University) Sukpan, Kornkanok (Department of Pathology, Faculty of Medicine, Chiang Mai University) Srisomboon, Jatupol (Department of Obstetrics and Gynecology, Faculty of Medicine, Chiang Mai University) Suprasert, Prapaporn (Department of Obstetrics and Gynecology, Faculty of Medicine, Chiang Mai University) Kasatpibal, Nongyao (Faculty of Nursing, Chiang Mai University) Khunamornpong, Surapan (Department of Pathology, Faculty of Medicine, Chiang Mai University) |
1 | Kantathavorn N, Kietpeerakool C, Suprasert P, et al (2008). Clinical relevance of atypical squamous cells of undetermined significance by the 2001 bethesda system: experience from a cervical cancer high incidence region. Asian Pac J Cancer Prev, 9, 785-8. |
2 | Katki HA, Schiffman M, Castle PE, et al (2013). Five-year risks of CIN 3+ and cervical cancer among women who test Pap-negative but are HPV-positive. J Low Genit Tract Dis, 17, 56-63. DOI |
3 | Kiatiyosnusorn R, Suprasert P, Srisomboon J, et al (2010). Highgrade histologic lesions in women with low-grade squamous intraepithelial lesion cytology from a region of Thailand with a high incidence of cervical cancer. Int J Gynaecol Obstet, 110, 133-6. DOI ScienceOn |
4 | Leinonen M, Kotaniemi-Talonen L, Anttila A, et al (2008). Prevalence of oncogenic human papillomavirus infection in an organised screening population in Finland. Int J Cancer, 123, 1344-9. DOI |
5 | Li J, Huang R, Schmidt JE, Qiao YL (2013). Epidemiological features of human papillomavirus (HPV) infection among women living in mainland China. Asian Pac J Cancer Prev, 14, 4015-23. 과학기술학회마을 DOI |
6 | Massad LS, Einstein MH, Huh WK, et al (2013). 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis, 17, 1-27. |
7 | Ogilvie GS, Krajden M, van Niekerk DJ, et al (2012). Primary cervical cancer screening with HPV testing compared with liquid-based cytology: results of round 1 of a randomised controlled trial-the HPV FOCAL Study. Br J Cancer, 107, 1917-24. DOI |
8 | Othman N, Othman NH (2014). Detection of human papillomavirus DNA in routine cervical scraping samples: use for a national cervical cancer screening program in a developing nation. Asian Pac J Cancer Prev, 15, 2245-9. 과학기술학회마을 DOI ScienceOn |
9 | Pan QJ, Hu SY, Zhang X, et al (2013). Pooled analysis of the performance of liquid-based cytology in populationbased cervical cancer screening studies in china. Cancer Cytopathol, 121, 473-82. DOI |
10 | Pandey S, Mishra M, Chandrawati (2012). Human papillomavirus screening in north Indian women. Asian Pac J Cancer Prev, 13, 2643-6. 과학기술학회마을 DOI ScienceOn |
11 | Rai AK, Das D, Kataki AC, et al (2014). Hybrid capture 2 assay based evaluation of high-risk HPV status in healthy women of north-east India. Asian Pac J Cancer Prev, 15, 861-5. 과학기술학회마을 DOI |
12 | Rashid RM, Dahlui M, Mohamed M, Gertig D (2013). Adapting the Australian system: is an organized screening program feasible in Malaysia?--an overview of cervical cancer screening in both countries. Asian Pac J Cancer Prev, 14, 2141-6. DOI ScienceOn |
13 | Ronco G, Giorgi-Rossi P, Carozzi F, et al (2006). Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. Lancet Oncol, 7, 547-55. DOI |
14 | Ronco G, Segnan N, Giorgi-Rossi P, et al (2006). Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst, 98, 765-74. DOI ScienceOn |
15 | Walboomers JM, Jacobs MV, Manos MM, et al (1999). Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol, 189, 12-9. DOI |
16 | Sankaranarayanan R, Nene BM, Shastri SS, et al (2009). HPV screening for cervical cancer in rural india. N Engl J Med, 360, 1385-94. DOI ScienceOn |
17 | Sharma M, Bruni L, Diaz M, et al (2013). Using HPV prevalence to predict cervical cancer incidence. Int J Cancer, 132, 1895-900. DOI ScienceOn |
18 | Swangvaree SS, Kongkaew P, Rugsuj P, Saruk O (2010). Prevalence of high-risk human papillomavirus infection and cytologic results in Thailand. Asian Pac J Cancer Prev, 11, 1465-8. |
19 | Wang Y, Yu YH, Shen K, et al (2014). Cervical cancer screening and analysis of potential risk factors in 43,567 women in Zhongshan, China. Asian Pac J Cancer Prev, 15, 671-6. 과학기술학회마을 DOI |
20 | Zhao FH, Lin MJ, Chen F, et al (2010). Performance of highrisk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from china. Lancet Oncol, 11, 1160-71. DOI ScienceOn |
21 | Zorzi M, Del Mistro A, Farruggio A, et al (2013). Use of a highrisk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study. BJOG, 120, 1260-7. DOI |
22 | Carestiato FN, Silva KC, Dimetz T, Oliveira LH, Cavalcanti SM (2006). Prevalence of human papillomavirus infection in the genital tract determined by hybrid capture assay. Braz J Infect Dis, 10, 331-6. |
23 | Arbyn M, Benoy I, Simoens C, et al (2009). Prevaccination distribution of human papillomavirus types in women attending at cervical cancer screening in Belgium. Cancer Epidemiol Biomarkers Prev, 18, 321-30. DOI |
24 | Arbyn M, Ronco G, Anttila A, et al (2012). Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine, 30, 88-99. DOI |
25 | Bulkmans NW, Berkhof J, Rozendaal L, et al (2007). Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year followup of a randomised controlled implementation trial. Lancet, 370, 1764-72. DOI ScienceOn |
26 | Castle PE, de Sanjose S, Qiao YL, et al (2012). Introduction of human papillomavirus DNA screening in the world: 15 years of experience. Vaccine, 30, 117-22. DOI |
27 | Castle PE, Fetterman B, Poitras N, et al (2009). Five-year experience of human papillomavirus DNA and Papanicolaou test cotesting. Obstet Gynecol, 113, 595-600. DOI |
28 | Curado MP, Edwards B, Shin HR, et al (2007). Cancer incidence in five continents, Vol. IX. Lyon: IARC Scientific Publications No.160. |
29 | Cuzick J, Clavel C, Petry KU, et al (2006). Overview of the european and north american studies on HPV testing in primary cervical cancer screening. Int J Cancer, 119, 1095-101. DOI ScienceOn |
30 | Cuzick J, Szarewski A, Cubie H, et al (2003). Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet, 362, 1871-6. DOI ScienceOn |
31 | Dudding N, Crossley J (2013). Sensitivity and specificity of HPV testing: what are the facts? Cytopathology, 24, 283-8. |
32 | Ferreccio C, Barriga MI, Lagos M, et al (2013). Screening trial of human papillomavirus for early detection of cervical cancer in Santiago, Chile. Int J Cancer, 132, 916-23. DOI |
33 | Franceschi S, Herrero R, Clifford GM, et al (2006). Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer, 119, 2677-84. DOI ScienceOn |
34 | Herrero R, Hildesheim A, Bratti C, et al (2000). Populationbased study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst, 92, 464-74. DOI ScienceOn |
35 | Ito K, Tsunematsu M, Satoh K, Kakehashi M, Nagata Y (2013). Effectiveness of cervical cancer screening based on a mathematical screening model using data from the Hiroshima Prefecture Cancer Registry. Asian Pac J Cancer Prev, 14, 4897-902. 과학기술학회마을 DOI ScienceOn |
36 | Jin XW, Lipold L, McKenzie M, Sikon A (2013). Cervical cancer screening: what's new and what's coming? Cleve Clin J Med, 80, 153-60. DOI |
37 | Junyangdikul P, Tanchotsrinon W, Chansaenroj J, et al (2013). Clinical prediction based on HPV DNA testing by hybrid capture 2 (HC2) in combination with liquid-based cytology (LBC). Asian Pac J Cancer Prev, 14, 903-7. 과학기술학회마을 DOI |
38 | Sukvirach S, Smith JS, Tunsakul S, et al (2003). Populationbased human papillomavirus prevalence in lampang and Songkla, thailand. J Infect Dis, 187, 1246-56. DOI ScienceOn |